Highly experienced translational tumour immunologist passionate about bringing transformative medicines to patients with cancer. Currently Director of Disease Biology at Peptone, leading a team of Biologists responsible for executing in vitro studies to support all aspects of preclinical development for novel biologic and small molecule therapeutics. Project Leader for two programmes; an engineered cytokine-mAb fusion in preclinical studies currently executing IND-enabling in vivo studies, and a novel small molecule campaign against a key oncology transcription factor in the early stages of target validation. Leading cross-functional teams, in addition to supporting the wider organisation as an expert drug discovery resource contributing to the mode of action work and building disease rationale for projects across the portfolio. Accountable for making quick and informed decisions, driving programmes forward by contributing to strategy, data review, delivering internal and external international presentations and leading key stakeholder management. Familiarity and enjoyment with working in a fast-growing matrixed international biotech environment, managing relationships and teams at all levels of a company hierarchy.I have a strong academic background in molecular genetics, tumour biology and immunology receiving my PhD at the University of York and completing post-doctoral training at the University Cambridge. Deep technical expertise across all aspects of translational biology, including advanced flow cytometry, in vitro 3D tissue culture systems, advanced microscopy and multiple in vivo pre-clinical model systems. I retain an avid fascination regarding stromal immunology and was the Co-founder and President of the Stromal Immunology Group, an official affinity group of the British Society of Immunology, for more than a decade.